Scientific Formulation
Jellyfos
The breakthrough in Bisphosphonate therapy. Jellyfos offers 'Jelly Convenience' to overcome the significant hurdles of traditional Alendronate tablets—eliminating choking hazards and the strict 30-minute upright requirement.
Molecular Composition
Alendronic Acid Jelly 70 mg
Therapeutic Matrix
- MHLW Japan Approved
- No Upright Position Required
- Bioequivalent to Oral Tablets
- Once-Weekly Pineapple Jelly
Mechanisms of Action
Alendronic Acid (Jelly Form)
Provides potent inhibition of osteoclast-mediated bone resorption with 90% fewer physical restrictions than tablets.
Enhanced Compliance
Easy-to-swallow pineapple flavored jelly ensures patient adherence in elderly and bedridden patients.
Clinical Advantage
MHLW Japan Approved formulation that shows better efficacy than Risedronate and Ibandronate without the choking hazards of oral tablets.
Precision Healthcare for Everyone
